Moderna (MRNA) Total Liabilities (2017 - 2026)

Moderna (MRNA) has 10 years of Total Liabilities data on file, last reported at $4.1 billion in Q1 2026.

• On a quarterly basis, Total Liabilities rose 54.66% year-over-year to $4.1 billion in Q1 2026; TTM through Mar 2026 was $4.1 billion, a 54.66% increase from a year earlier, with the FY2025 full-year figure at $3.7 billion, up 13.79% from the prior year.
• Total Liabilities for Q1 2026 stood at $4.1 billion, up from $3.7 billion in the prior quarter.
• Over the last five years, Total Liabilities for MRNA reached as high as $10.5 billion in Q1 2022 and fell as low as $2.6 billion in Q2 2025.
• Historically, Total Liabilities has averaged $5.0 billion across 5 years, with a median of $4.1 billion in 2026.
• Across the five-year window, Total Liabilities plunged 50.05% in 2023 and surged 54.66% in 2026, its largest moves.
• Year by year, Total Liabilities stood at $6.7 billion in 2022, then plunged by 32.12% to $4.6 billion in 2023, then decreased by 29.11% to $3.2 billion in 2024, then rose by 13.79% to $3.7 billion in 2025, then climbed by 10.63% to $4.1 billion in 2026.
• Per Business Quant data, the three most recent Total Liabilities figures were $4.1 billion in Q1 2026, $3.7 billion in Q4 2025, and $2.8 billion in Q3 2025.